AimedBio
AimedBio is a Seoul-based clinical-stage biopharmaceutical company, spun off from Samsung Medical Center in 2018, that develops proprietary antibody-drug conjugates (ADCs) for cancer and out-licenses them to global pharmaceutical partners including Biohaven, Boehringer Ingelheim, and SK Plasma.
- Company typePublic
- Founded2018
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AimedBio does
AimedBio Inc. (주식회사 에임드바이오) is a Seoul-based clinical-stage biopharmaceutical company founded in August 2018 as a spin-off from Samsung Medical Center, specializing in antibody-drug conjugate (ADC) therapeutics for cancer. The company builds on its origin at Samsung Medical Center to operate a proprietary P-ADC™ (Precision-driven ADC) platform that integrates patient-derived cell (PDC) and patient-derived xenograft (PDX) validation into every stage of ADC development — from unmet-needs-based target discovery and antibody engineering through linker-payload optimization, translational research, and candidate selection. Its internal pipeline centers on two lead assets: AMB302, a first-in-class FGFR3-targeted ADC for bladder, head/neck cancer, and glioblastoma (exclusively licensed to Biohaven as BHV-1530 with FDA IND, MFDS IND, and FDA Orphan Drug Designation), and AMB303, a best-in-class ROR1 ADC for solid tumors using a co-developed Topo I inhibitor payload (AMB402) with Samsung Biologics. AimedBio also develops proprietary payloads (AMB401 duocarmycin, AMB402 camptothecin), an AVATASCAN® precision-medicine screening service, and a BsADC bispecific platform (PP1/PP2/PP3).
The company's business model is asset-centric B2B licensing rather than direct commercialization. AimedBio develops differentiated ADC candidates internally and out-licenses global rights to large pharmaceutical partners, generating revenue from upfront payments, development and regulatory milestones, sales milestones, and royalties. Confirmed licensing agreements include Biohaven for AMB302 (January 2025), Boehringer Ingelheim for a KRAS-mutant solid-tumor ADC valued up to $991 million (October 2025), and a co-development and option-to-license arrangement with SK Plasma for AMB303 (June 2025, option exercised December 2025). Additional revenue derives from co-development partnerships (Samsung Biologics, GeneQuantum, GC Cell, Sovargen) and Korean government grants via the Korea Drug Development Fund (KDDF).
Following a ₩40 billion Series B (July 2024), a ₩51.1 billion pre-IPO round (June 2025), and a ₩70.73 billion KOSDAQ IPO in December 2025 — the largest biotech listing on the exchange that year — AimedBio operates from headquarters in Songpa-gu, Seoul, with a wholly owned Singapore subsidiary (AVATAMED PTE Ltd.) supporting AVATASCAN® international commercialization. FY2025 consolidated revenue reached ₩47.3 billion (up from ₩11.76 billion in FY2024), with operating income of ₩20.8 billion versus a ₩408 million loss the prior year. The company is publicly traded on KOSDAQ under ticker 0009K0, with 64.67 million shares outstanding and a strategic shareholder base anchored by Samsung Life Science Fund, Yuhan Corporation, Intervest, and DS Asset Management.
AimedBio firmographics
Firmographics- Name
- AimedBio
- Legal name
- 주식회사 에임드바이오
- Website
- https://aimedbio.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AimedBio is a Seoul-based clinical-stage biopharmaceutical company, spun off from Samsung Medical Center in 2018, that develops proprietary antibody-drug conjugates (ADCs) for cancer and out-licenses them to global pharmaceutical partners including Biohaven, Boehringer Ingelheim, and SK Plasma.
- Ownership category
- akta.pro rank
AimedBio industry classification
Industry- Product category
- Biopharmaceutical Oncology Drug Development
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where AimedBio is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
AimedBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Technology Licensing & Transfer: The company generates revenue through licensing out ADC assets to global pharmaceutical companies. This includes upfront payments, development milestones, regulatory milestones, and royalties on future sales. Key deals include Biohaven (AMB302) and Boehringer Ingelheim (ADC asset).
- Co-development Revenue: Revenue from co-development partnerships where AimedBio contributes research/development capabilities in exchange for development funding, milestone payments, and shared commercialization rights. Partners include SK Plasma (AMB303), GeneQuantum, and Samsung Biologics.
- Government Grants: Funding from Korea Drug Development Fund (KDDF) and other government programs supporting ADC development and brain disease treatments.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
AimedBio product offering
Product offeringCore offering
AimedBio develops antibody-drug conjugate (ADC) therapeutics for solid tumors using its proprietary P-ADC™ platform, which leverages patient-derived cell and xenograft models for target discovery, antibody engineering, ADC optimization, and translational research. The company generates revenue by licensing ADC candidates (AMB302, ODS025) and entering co-development agreements (AMB303) with global pharmaceutical companies such as Biohaven, Boehringer Ingelheim, and SK Plasma, while also providing AVATASCAN® precision medicine screening services.
Product overview
AimedBio is a biopharmaceutical company operating as a spin-off from Samsung Medical Center, developing a portfolio of antibody-drug conjugate (ADC) therapies through its proprietary P-ADC™ platform. The platform enables end-to-end ADC development from patient-derived target identification through clinical validation, supporting multiple pipeline candidates including AMB302 (FGFR3 ADC, licensed to Biohaven), AMB303 (ROR1 ADC), and ODS025 (licensed to Boehringer Ingelheim). The company also offers AVATASCAN® precision medicine screening services and develops proprietary payload technologies (AMB401 duocarmycin, AMB402 camptothecin).
Differentiator
Problem solved
Functional benefit
Brands
- P-ADC™: Proprietary precision-driven ADC development platform utilizing patient-derived models for target discovery, antibody engineering, and ADC optimization
- AVATASCAN®
- AMB302
- AMB303
- ODS025
Products and services
- P-ADC™ Platform End-to-end ADC development platform using patient-derived models for target discovery, antibody engineering, ADC optimization, and translational research. Available for licensing and co-development engagements with pharmaceutical partners.
- AVATASCAN® Precision Medicine Screening Service Precision medicine screening technology providing medical research services for cancer and disease research, using patient-derived avatars to identify root causes and develop new therapeutic possibilities for pharmaceutical and biotech customers.
- AMB302 (BHV-1530) - FGFR3 ADC First-in-class FGFR3-targeted antibody-drug conjugate for solid tumors including bladder cancer, head and neck cancer, and glioblastoma, with wide therapeutic index. Licensed exclusively to Biohaven for global development and commercialization as BHV-1530.
- AMB303 - ROR1 ADC Best-in-class ROR1-targeted ADC for solid tumors where ROR1 is overexpressed, including lung, breast, and ovarian cancer. Uses self-developed anti-ROR1 antibody with co-developed Topo I inhibitor payload (AMB402) from Samsung Biologics collaboration. Co-developed with SK Plasma.
- ODS025 - Anti-KRAS Solid Tumor ADC ADC candidate for solid tumors targeting KRAS mutations in lung, colorectal, and breast cancer. Licensed to Boehringer Ingelheim for global development and commercialization in a deal valued up to $991 million including upfront, development/regulatory/commercial milestones, and royalties.
Quantifiable outcome
- 107% survival extension in preclinical monotherapy studies for AMB302
- +3 more outcomes
Companies that use AimedBio
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
AimedBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
AimedBio partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered major, core and minor.
- GaluxmajorInvestment and joint research agreement to develop blood-brain barrier-crossing protein delivery platform. Combines Galux's AI protein design platform (GaluxDesign) with AimedBio's ADC development capabilities to enable antibody/protein therapeutics to reach brain tissue.
- Sovargen (소바젠)majorJoint development of Antibody-Oligonucleotide Conjugates (AOC) expanding from ADC to gene regulation therapeutics. Combines AimedBio's patient-derived cell-based antibody/target discovery with Sovargen's oligonucleotide design and manufacturing. Targeting oncology, metabolic, immune, and rare diseases.
- AIVIS (Avis)majorJoint research agreement using AIVIS's AI-based digital pathology solution 'Qanti Discovery' to quantify pathology data and enhance biomarker-focused patient selection strategies. Includes strategic equity investment. Aims to improve clinical success probability through AI-based companion diagnostics.
- Boehringer IngelheimcoreGlobal licensing agreement for ADC asset targeting KRAS mutations in various solid tumors. Total deal value up to $991 million including upfront, development/regulatory/commercial milestones, and royalties. Candidate uses Topo1 inhibitor payload with aim to enter Phase 1 in 2026.
- SK PlasmacoreCo-development and license option agreement for AMB303 (ROR1 ADC). SK Plasma exercises option for global co-commercialization rights. AimedBio handles basic research and candidate discovery; SK Plasma leads clinical and commercialization development. Option exercise fee received December 2025.
- BiohavencoreExclusively licensed global development and commercialization rights for AMB302 (FGFR3 ADC, now BHV-1530) to Biohaven. AimedBio had planned to conduct clinical trials independently but partnered to leverage Biohaven's global clinical capabilities, enhancing probability of success. Deal terms confidential.
- Samsung BiologicscoreEquity investment through Samsung Life Science Fund plus R&D agreements to develop ADC technologies and monoclonal antibody therapies. Jointly developed Topo I inhibitor payload (AMB402). Plans for ADC manufacturing facility by 2024.
- GeneQuantum (진퀀텀)majorCo-development of AMB302 combining AimedBio's antibody with GeneQuantum's linker-payload and conjugation technology. Extended in June 2023 to potentially develop up to 5 additional ADCs. Enables brain tumor targeting ADC development.
- GC CellminorCAR-NK cell therapy co-development using AimedBio's cancer-specific protein-binding antibody (AMB015) for CAR-NK therapy candidates. Expands beyond ADC into cell therapy domain.
- AVATAMED PTE Ltd (Singapore)minorSubsidiary established in Singapore for commercialization of precision medicine screening technology (AVATASCAN) in international markets.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
AimedBio competitors and assessment
Company assessmentDirect peers
- Pyxis Oncology: Clinical-stage ADC and immuno-oncology biotech developing novel ADC candidates. Comparable business model of developing ADC pipeline assets and pursuing partnership/licensing opportunities with larger pharmaceutical companies.
- Tubulis: Emerging ADC platform company developing differentiated conjugation chemistries and payload technologies for ADCs. Comparable technology-platform approach to AimedBio's P-ADC™, both targeting out-licensing to global pharma.
- ProfoundBio: Clinical-stage ADC company developing next-generation antibody conjugates with proprietary linker-payload technology. Acquired by Genmab in 2024, illustrating the strategic value placed on differentiated ADC platforms similar to AimedBio's positioning.
- GeneQuantum Healthcare: Chinese ADC technology company specializing in site-specific conjugation and linker-payload technology. Already partnered with AimedBio on AMB302 development, demonstrating peer-level technology capabilities and shared customer base in global pharma.
- Mersana Therapeutics: Clinical-stage ADC-focused biotech developing first-in-class and best-in-class ADC candidates across multiple tumor targets. Directly comparable to AimedBio as a similarly sized pure-play ADC developer pursuing licensing deals with major pharma.
Emerging players
- Bolt Biotherapeutics: ADC platform company developing immune-stimulating antibody conjugates with proprietary linker technology. Similar technology-platform approach and clinical stage to AimedBio's preclinical-to-Phase 1 pipeline.
- Biohaven: Clinical-stage biopharma that licensed AMB302 (now BHV-1530) from AimedBio and is developing FGFR3 ADC in-house. Comparable size and stage, with similar strategy of in-licensing differentiated ADC assets for clinical development.
Regional players
- LegoChem Biosciences: Korean ADC platform company developing proprietary linker technology and ADC candidates. Direct regional comparable also pursuing licensing deals with global pharma, with overlapping investor base and Korean biotech ecosystem positioning.
Broad incumbents
- Innovent Biologics: Chinese biopharma with growing ADC pipeline and multiple licensing deals with global pharma including Eli Lilly. Comparable Asian-region origin and strategy of building ADC portfolio for global out-licensing, though larger scale and broader therapeutic focus.
- Daiichi Sankyo: Global ADC leader with Enhertu and Datroway, partnered with AstraZeneca. While a customer/partner candidate rather than competitor, Daiichi sets the licensing benchmark that AimedBio's platform output is benchmarked against.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
AimedBio social profiles
Digital presenceAimedBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
AimedBio leadership team
Management profileNumber of profiles
Profiles13 records
AimedBio subsidiaries and ownership
Company hierarchySubsidiaries1 record
AimedBio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AimedBio M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AimedBio
What does AimedBio do?
AimedBio develops antibody-drug conjugate (ADC) therapeutics for solid tumors using its proprietary P-ADC™ platform, which leverages patient-derived cell and xenograft models for target discovery, antibody engineering, ADC optimization, and translational research. The company generates revenue by licensing ADC candidates (AMB302, ODS025) and entering co-development agreements (AMB303) with global pharmaceutical companies such as Biohaven, Boehringer Ingelheim, and SK Plasma, while also providing AVATASCAN® precision medicine screening services.
Is AimedBio a public or private company?
AimedBio is a public company. It is classified as public and is currently operating.
When was AimedBio founded?
AimedBio was founded in 2018. It employs 11 to 50 people.
Where is AimedBio based?
AimedBio is headquartered in Seoul, South Korea, in the Asia region.
How does AimedBio make money?
Three revenue lines are on record. Technology Licensing & Transfer is the primary driver. The others are co-development Revenue and government Grants.
Who are AimedBio's main competitors?
Direct peers on record are Pyxis Oncology, Tubulis, ProfoundBio, GeneQuantum Healthcare and Mersana Therapeutics. Emerging players are Bolt Biotherapeutics and Biohaven. LegoChem Biosciences is listed as a regional player. Broad incumbents are Innovent Biologics and Daiichi Sankyo.
Does AimedBio have an API?
No public API is recorded for AimedBio.
What industry is AimedBio in?
AimedBio's product category is Biopharmaceutical Oncology Drug Development. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.